BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer (LABC). Patients with IBC commonly present with skin metastasis, which are observed microscopically as tumor emboli within dermal lymphatics. These metastatic tumor cells aberrantly overexpress E-cadherin and exhibit the ability to undergo self-renewal and are highly invasive. There are no therapeutics yet identified that target the structure and functions of IBC tumor emboli. The present studies evaluated the effects of the pan-histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) using IBC tumor spheroids derived from established IBC cell lines and tumor spheroids derived from pleural effusion (PE) aspirates of patients with IBC and LABC, designated as PE-IBC and PE-LABC. METHODS: Methods used are as follows: culture of IBC cells from clonal density single cells in low adherence culture conditions that promote formation of IBC tumor spheroids; clonogenic assays; cell fractionation and Western blotting; confocal microscropy; and modified Boyden chamber invasion assays. RESULTS: SAHA inhibited self-renewal of IBC tumor spheroids from established IBC cell lines and PE-IBC and PE-LABC, as assessed by decreased clonogenic growth. SAHA blocked homotypic aggregation of the cells that comprised the IBC tumor spheroids leading to loss of their 3-dimensional (3D) structure, which was associated with a change in location of E-cadherin protein from the plasma membrane in untreated IBC tumor spheroids to the cytoplasm of cells within IBC tumor spheroids with SAHA treatment. In addition, SAHA blocked the robust invasion exhibited by IBC tumor spheroids of established cell lines as well as by tumor spheroids derived from PE-IBC and PE-LABC. CONCLUSIONS: SAHA targets the integrity and biological activities of IBC tumor spheroids and may be a promising agent to evaluate for its effectiveness in treatment of IBC. Copyright 2010 American Cancer Society.
BACKGROUND:Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer (LABC). Patients with IBC commonly present with skin metastasis, which are observed microscopically as tumor emboli within dermal lymphatics. These metastatic tumor cells aberrantly overexpress E-cadherin and exhibit the ability to undergo self-renewal and are highly invasive. There are no therapeutics yet identified that target the structure and functions of IBC tumor emboli. The present studies evaluated the effects of the pan-histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) using IBC tumor spheroids derived from established IBC cell lines and tumor spheroids derived from pleural effusion (PE) aspirates of patients with IBC and LABC, designated as PE-IBC and PE-LABC. METHODS: Methods used are as follows: culture of IBC cells from clonal density single cells in low adherence culture conditions that promote formation of IBC tumor spheroids; clonogenic assays; cell fractionation and Western blotting; confocal microscropy; and modified Boyden chamber invasion assays. RESULTS:SAHA inhibited self-renewal of IBC tumor spheroids from established IBC cell lines and PE-IBC and PE-LABC, as assessed by decreased clonogenic growth. SAHA blocked homotypic aggregation of the cells that comprised the IBC tumor spheroids leading to loss of their 3-dimensional (3D) structure, which was associated with a change in location of E-cadherin protein from the plasma membrane in untreated IBC tumor spheroids to the cytoplasm of cells within IBC tumor spheroids with SAHA treatment. In addition, SAHA blocked the robust invasion exhibited by IBC tumor spheroids of established cell lines as well as by tumor spheroids derived from PE-IBC and PE-LABC. CONCLUSIONS:SAHA targets the integrity and biological activities of IBC tumor spheroids and may be a promising agent to evaluate for its effectiveness in treatment of IBC. Copyright 2010 American Cancer Society.
Authors: F Forozan; E H Mahlamäki; O Monni; Y Chen; R Veldman; Y Jiang; G C Gooden; S P Ethier; A Kallioniemi; O P Kallioniemi Journal: Cancer Res Date: 2000-08-15 Impact factor: 12.701
Authors: Thehang H Luu; Robert J Morgan; Lucille Leong; Dean Lim; Mark McNamara; Jana Portnow; Paul Frankel; David D Smith; James H Doroshow; Carol Wong; Ana Aparicio; David R Gandara; George Somlo Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Massimo Cristofanilli; Vicente Valero; Aman U Buzdar; Shu-Wan Kau; Kristine R Broglio; Ana Maria Gonzalez-Angulo; Nour Sneige; Rabiul Islam; Naoto T Ueno; Thomas A Buchholz; Sonja E Singletary; Gabriel N Hortobagyi Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Michael A Pereira; Blake M Warner; Thomas J Knobloch; Christopher M Weghorst; Ronald A Lubet; Vernon E Steele; Bruce C Casto Journal: Int J Cancer Date: 2012-01-31 Impact factor: 7.396
Authors: Kim Tran; Renee Risingsong; Darlene B Royce; Charlotte R Williams; Michael B Sporn; Patricia A Pioli; Lalji K Gediya; Vincent C Njar; Karen T Liby Journal: Carcinogenesis Date: 2012-10-06 Impact factor: 4.944